Drug Profile


Alternative Names: ANX-188; CRL-5861; FLOCOR; MST-188; Poloxamer 188 NF; Purified 188; Purified poloxamer 188

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator CytRx Corporation
  • Developer Mast Therapeutics
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Cell membrane structure modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Veno-occlusive disorders
  • Phase II Myocardial infarction
  • Preclinical Stroke
  • No development reported Acute lung injury; Cancer; CNS disorders; Muscular dystrophies; Peripheral nervous system diseases
  • Discontinued Chronic heart failure; Peripheral arterial occlusive disorders; Sickle cell anaemia

Most Recent Events

  • 08 Nov 2016 Discontinued - Phase-II for Chronic heart failure in Australia (IV)
  • 08 Nov 2016 Discontinued - Phase-II for Chronic heart failure in USA (IV)
  • 08 Nov 2016 Discontinued - Phase-III for Sickle cell anaemia (In adolescents, In children, In adults) in USA, Belgium, Turkey, Jordan, Jamaica, Brazil, Dominican Republic, Spain, Panama, Oman, Lebanon (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top